RegCell has developed a proprietary epigenetic reprogramming platform to generate stable, antigen-specific regulatory T cells (Tregs) intended to restore immune tolerance in autoimmune diseases and transplantation. The platform emphasizes epigenetic (non‑genetic) reprogramming to simplify manufacturing, enhance safety, and enable scalable production versus genetic modification approaches. RegCell plans to initiate a first-in-human clinical trial in 2025 for an antigen-specific autoimmune indication. Financially, the company closed an oversubscribed $8.5M seed financing and was awarded up to $37.3M (¥5.6 billion) in non-dilutive funding from Japan’s AMED to support IND-enabling studies, GMP optimization, and clinical proof-of-concept in the U.S. The company completed a strategic transition to a U.S.-based corporation with newly established U.S. headquarters in Emeryville, Calif., while continuing core scientific operations in Japan. RegCell is led by CEO Dr. Michael McCullar and was founded on discoveries by Professor Shimon Sakaguchi.

Total raised

$47M

Funding rounds

2

Latest round

Seed

Latest activity

Mar 2025